[1] TAM P M, YOUNG A L, CHENG L L, et al. Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis: case series[J]. Br J Ophthalmol,2010,94(10):1405-1406. doi:  10.1136/bjo.2009.172387
[2] TADDIO A, CIMAZ R, CAPUTO R, et al. Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series[J]. Pediatr Rheumatol Online J,2011,9(1):34. doi:  10.1186/1546-0096-9-34
[3] ZHENG X P, ZHANG X, LIU X J, et al. Patient with neuromyelitis optica spectrum disorder combined with Sjögren's syndrome relapse free following tacrolimus treatment[J]. Intern Med,2014,53(20):2377-2380. doi:  10.2169/internalmedicine.53.0814
[4] 林昕, 张佳良, 宋洪涛. 他克莫司阳离子微乳原位凝胶的制备及体外释放研究[J]. 药学实践杂志, 2020, 38(4):307-311,317. doi:  10.12206/j.issn.1006-0111.201911075
[5] 张晶. 他克莫司体温敏感眼用凝胶的研究[D]. 沈阳: 沈阳药科大学, 2008.
[6] 杜有云. 地塞米松眼用微乳凝胶的制备及评价[D]. 广州: 广东药科大学, 2017.
[7] 霍涛涛. 他克莫司增溶体系的构建与评价[D]. 福州: 福建医科大学, 2018.
[8] YUAN J, ZHAI J J, CHEN J Q, et al. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration[J]. J Ocul Pharmacol Ther,2009,25(4):345-350. doi:  10.1089/jop.2008.0125
[9] ZAMBITO Y, DI COLO G. Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone[J]. Eur J Pharm Biopharm,2010,75(2):194-199. doi:  10.1016/j.ejpb.2010.02.006
[10] ZENG W, LI Q, WAN T, et al. Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability[J]. Colloids Surf B Biointerfaces,2016,141:28-35. doi:  10.1016/j.colsurfb.2016.01.014